Preservative-free preparation may improve adherence


Tafluprost 0.0015% is safe, effective and well-tolerated in routine clinical practice

To date, prostaglandin analogues (PGAs) have become the most common medical treatment worldwide to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. PGAs have a strong, sustained and stable IOPlowering effect and a generally well tolerated systemic safety profile.

Tafluprost 0.0015% is the first and only PGA that is available in a preservative-free formulation. We evaluated the efficacy, local tolerability and safety of preservative-free tafluprost 0.0015% (Taflotan) in a routine clinical setting.1

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.